BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.0%

Neg 0% Neu 84% Pos 0%

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.

Comments

No comments yet. Be the first!